文献速递母胎医学产科

扩展性无创产前筛查用于显性单基因病的原理验证、性能与挑战

Expanded noninvasive prenatal screening for dominant single-gene disorders: proof-of-concept, performance, and challenges.
PubMed 文献 · Am J Obstet Gynecol · 2025-06-21

本研究对750例超声异常孕妇的血浆样本行155基因面板无创产前筛查202种显性单基因病,阳性32例经产前诊断确认1例假阳性、无假阴性,灵敏度100.0%、特异度99.9%、阳性预测值96.9%、阴性预测值100.0%;7例(22.6%)阳性涉及既往面板未覆盖基因。作者指出该筛查不能替代侵入性诊断,尤其对高变异等位基因频率变异,且需在低危人群中进一步研究。

要点

  • 155基因面板无创产前筛查202种显性单基因病在高危孕妇中技术可行。
  • 灵敏度100.0%、特异度99.9%、阳性预测值96.9%、阴性预测值100.0%。
  • 变异等位基因频率>20%的变异需母体携带者验证以排除假阳性。

核心结论

  • 本研究在高危队列中证明扩展性无创产前筛查202种显性单基因病的技术可行性和临床性能。
  • 该筛查面板不能替代侵入性诊断操作的必要性,尤其对高变异等位基因频率变异。
  • 三联全基因组测序/全外显子组测序确认可增强变异解读。
  • 需要在低危人群中进一步研究以评估该筛查的临床效用并指导其与现有产前筛查策略的整合。

研究设计与样本

  • 对750例有明确超声异常的孕妇血浆样本行202种显性单基因病的无创产前筛查。
  • 使用独特分子标识符进行测序错误校正。
  • 所有参与者均经羊水样本全基因组测序或全外显子组测序进行确认性产前诊断。
  • 根据等位基因频率对无创产前筛查识别的变异进行分类,计算灵敏度、特异度、阳性预测值和阴性预测值。

主要发现

  • 750例高危妊娠中,无创产前筛查202种显性单基因病识别32例阳性病例。
  • 后续产前诊断确认1例假阳性、无假阴性,灵敏度100.0%(95%CI 100.0%至100.0%),特异度99.9%(95%CI 99.6%至100.1%)。
  • 阳性预测值为96.9%,阴性预测值为100.0%。
  • 7例(22.6%)确认阳性病例涉及既往筛查面板未覆盖的基因。
  • 变异等位基因频率>20%的变异需母体携带者验证以排除潜在假阳性结果;1例初判为意义不明变异的阴性病例经三联全基因组测序/全外显子组测序分析后重分类为可能致病。

临床怎么用

  • 作者指出该筛查面板不能替代侵入性诊断操作的必要性,尤其对高变异等位基因频率变异。
  • 作者指出三联全基因组测序/全外显子组测序确认可增强变异解读。
  • 作者指出需要在低危人群中进一步研究以评估临床效用并指导与现有产前筛查策略的整合。

局限性

  • 既往研究受限于小基因面板和不完整随访数据,妨碍准确评估筛查性能。
  • 本研究在高危队列中开展,需在低危人群中进一步研究以评估临床效用。
  • 该筛查面板不能替代侵入性诊断操作,尤其对高变异等位基因频率变异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Noninvasive prenatal screening for single-gene disorders is an emerging tool that might complement traditional aneuploidy screening by providing earlier, safer insights to invasive diagnostic methods, such as amniocentesis and chorionic villus sampling. However, previous studies were limited by small gene panels and incomplete follow-up data, hindering the accurate assessment of screening performance. OBJECTIVE: This study aimed to demonstrate the technical feasibility and evaluate the potential clinical performance of noninvasive prenatal screening for 202 dominant single-gene disorders using an expanded 155-gene panel in high-risk pregnancies, while also addressing limitations of prior studies, particularly in the calculation of positive predictive value and negative predictive value. STUDY DESIGN: We conducted noninvasive prenatal screening for 202 dominant single-gene disorders on 750 maternal plasma samples from pregnant women with definitive ultrasound abnormalities. Unique molecular identifiers were used for sequencing error correction. All participants underwent confirmatory prenatal diagnostic testing via whole genome sequencing or whole exome sequencing of amniotic fluid samples. Variants identified through noninvasive prenatal screening for single-gene disorders were classified based on allele frequencies, and performance metrics (sensitivity, specificity, positive predictive value, and negative predictive value) were calculated to evaluate the efficacy of the screening approach. RESULTS: Among 750 high-risk pregnancies, noninvasive prenatal screening for 202 dominant single-gene disorders identified 32 positive cases. Subsequent prenatal diagnosis confirmed one false positive and no false negatives, yielding a sensitivity of 100.0% (95% confidence interval, 100.0% to 100.0%) and a specificity of 99.9% (95% confidence interval, 99.6% to 100.1%). The positive predictive value and negative predictive value were 96.9% and 100.0%, respectively. Notably, 7 (22.6%) confirmed positive cases involved genes not covered in previous screening panels. Variant with a variant allele frequency >20% required maternal carrier verification to rule out potential false-positive results. A negative case initially classified as a variant of uncertain significance was reclassified as likely pathogenic following trio whole genome sequencing/whole exome sequencing analysis. CONCLUSION: This study demonstrated the technical feasibility and clinical performance of an expanded noninvasive prenatal screening for 202 dominant single-gene disorders in the high-risk cohort. However, this screening panel does not replace the need for invasive diagnostic procedures, particularly for high variant allele frequency variants, and confirmatory trio whole genome sequencing/whole exome sequencing enhanced variant interpretation. Further studies in low-risk populations are needed to assess the clinical utility of this screening and to guide its appropriate integration with existing prenatal screening strategies.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Chen S, Xu W, Zhang L, et al. Expanded noninvasive prenatal screening for dominant single-gene disorders: proof-of-concept, performance, and challenges. Am J Obstet Gynecol. 2025. PMID: 40550458. doi:10.1016/j.ajog.2025.06.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。